PURPOSE: Friends of Cancer Research (Friends) convened 12 data partners in a collaborative effort, titled Real World Evidence (RWE) Pilot 2.0, to evaluate outcomes for advanced non-small cell lung cancer (NSCLC) population receiving stand of care systemic frontline therapies. This collaboration evaluated real-world oncology data including claims-based datasets, electronic health records, and data captured by prior authorization systems and cancer registries. The workshop will share learnings specific to identification of variability between data sources, the methodological considerations to address differences and align populations for comparison of outcomes, and focus on the potential path forward to harmonize data across various sources, developing a common language across real-world data sources to improve utilization of these data.

DESCRIPTION: The workshop will begin with an introduction to the Friends RWE Pilot 2.0, including an overview of data source types used, followed by:

1) Dr. Mishra-Kalyani will present the inherent heterogeneity of data sources, with particular emphasis on how data sources and sampling frames may account for differences observed in findings;

2) Dr. Natanzon will provide a deeper dive into the data sets used in the Friends RWE Pilot 2.0 – describing the application of specific variable definitions to demonstrate how data heterogeneity across real world datasets (RWD) affects what attributes can be measured and analyzed, and thus potentially impact the results of the pilot; and

3) Dr. Robert will help us envision the path forward – how we can harmonize the various data sets so there are common terms/endpoints to leverage the growing amount and diversity of RWD while allowing for meaningful cross-analyses.

We will reserve the last 15 minutes for audience participation through moderated Q&A. In addition, we will utilize real-time polling, where results will be discussed with a focus on deriving insights on how to improve utilization of RWD.